Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience-Reference-Cited by-同舟云学术

Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience

Published:2019-07-03 Issue:3 Volume:9 Page:553-569
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Huang Yi-Wei,Tsai Tsen-Fang^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

http://link.springer.com/content/pdf/10.1007/s13555-019-0310-5.pdf

Reference58 articles.

1. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12.

2. Ko W-C, Tsai T-F, Tang C-H. Health state utility, willingness to pay, and quality of life among Taiwanese patients with psoriasis. Dermatol Sin. 2016;34(4):185–91.

3. Tsai T-F, Ho J-C, Chen Y-J, et al. Health-related quality of life among patients with moderate-to-severe plaque psoriasis in Taiwan. Dermatol Sin. 2018;36(4):190–5.

4. Bechet PE. Psoriasis: a brief historical review. Arch Dermatol Syphilol. 1936;33(2):327–34.

5. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–53.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling multifaceted roles of myeloid innate immune cells in the pathogenesis of psoriasis;Molecular Aspects of Medicine;2024-10

2. Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis;Dermatology and Therapy;2024-07-29

3. Clinical implication of tissue-resident memory T cells in psoriasis;Journal of the Korean Society for Psoriasis;2024-06-30

4. Inflammatory Memory in Chronic Skin Disease;JID Innovations;2024-05

5. Early intervention and disease modification in atopic dermatitis—the current state of the field and barriers to progress;Journal of the European Academy of Dermatology and Venereology;2023-12-08